Markus Hosang
Chairman at Unitectra Ltd.
Network origin in Markus Hosang first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.
16
| Subsidiary | Medical Specialties | 16 |
BioMedPartners AG
 BioMedPartners AG Investment ManagersFinance BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector.
15
| Private Company | Investment Managers | 15 |
Aleva Neurotherapeutics SA
 Aleva Neurotherapeutics SA Electronic Equipment/InstrumentsElectronic Technology Aleva Neurotherapeutics SA develops next-generation implants for deep brain stimulation therapy. Its micro fabricated devices enable target specific stimulation and optimization of current therapies. The company was founded by Claudio Pollo, Jean-Pierre Rosat, Philipe Renaud, Paul Pyzowski and André Mercanzini and in August 2008 and is headquartered in Lausanne, Switzerland.
13
| Holding Company | Electronic Equipment/Instruments | 13 |
AYOXXA Biosystems GmbH
 AYOXXA Biosystems GmbH BiotechnologyHealth Technology AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.
12
| Private Company | Biotechnology | 12 |
ImmunOs Therapeutics AG
 ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.
11
| Holding Company | Biotechnology | 11 |
Okairos AG
 Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland.
10
| Subsidiary | Pharmaceuticals: Major | 10 |
Unitectra Ltd.
 Unitectra Ltd. Miscellaneous Commercial ServicesCommercial Services Unitectra Ltd. operates as a technology transfer organization. It specializes in licensing, research contracts, IP management, start-up consulting and pre-seed financing. The company was founded by Adrian Sigrist in 1999 and is headquartered in Zurich, Switzerland.
10
| Private Company | Miscellaneous Commercial Services | 10 |
Anergis SA
 Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland.
8
| Holding Company | Pharmaceuticals: Generic | 8 |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Markus Hosang via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ROCHE HOLDING AG | Pharmaceuticals: Major | Sales & Marketing Director/Board Member Corporate Officer/Principal Corporate Officer/Principal General Counsel | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| The American University of Rome | College/University | Undergraduate Degree Doctorate Degree Corporate Officer/Principal | |
CEVEC Pharmaceuticals GmbH
 CEVEC Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
| EVOTEC SE | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
Knoll AG
 Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
| École Polytechnique Fédérale de Lausanne | College/University | Graduate Degree Doctorate Degree | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Sales & Marketing Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| SANTHERA PHARMACEUTICALS HOLDING AG | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
| University of Toronto | College/University | Doctorate Degree Masters Business Admin Undergraduate Degree | |
| INSEAD | College/University | Director/Board Member Masters Business Admin Masters Business Admin | |
| Universität zu Köln | College/University | Doctorate Degree Doctorate Degree | |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| BIOFRONTERA AG | Pharmaceuticals: Major | Chairman Director/Board Member | |
| University of St. Gallen | College/University | Masters Business Admin Masters Business Admin Graduate Degree | |
Novartis Venture Funds
 Novartis Venture Funds Investment ManagersFinance Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz. | Investment Managers | Chief Investment Officer Private Equity Investor Chief Investment Officer | |
| University of Basel | College/University | Doctorate Degree Doctorate Degree Graduate Degree Undergraduate Degree Graduate Degree Corporate Officer/Principal Doctorate Degree | |
| University of Zurich | College/University | Director/Board Member Doctorate Degree | |
| University of Geneva | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree | |
| SYMETIS SA | Biotechnology | Director/Board Member Director/Board Member | |
Scienion AG
 Scienion AG BiotechnologyHealth Technology Scienion AG develops and provides DNA biochips and protein microarrays. It provides its customers in the pharmaceutical, biotech, diagnostic and reagent supply markets, as well as in academic research institutions with products, and services to facilitate confidence and efficiency in aspects of its applications. The company was founded by Holger Eickhoff in 2000 and is headquartered in Dortmund, Germany. | Biotechnology | Chairman Chairman | |
Creathor Venture Management GmbH
 Creathor Venture Management GmbH Investment ManagersFinance Creathor Venture Management GmbH is an independent private equity firm specialized in technology venture capital investing. Creathor was foundedi n 2003 and is headquartered in Bad Homburg near Frankfurt in central Germany. The management invests their own capital, and manages venture capital funds on behalf of institutions. | Investment Managers | Private Equity Investor Private Equity Investor | |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
| MERUS N.V. | Biotechnology | Chairman Director/Board Member | |
binx health, inc.
 binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Information Technology Services | Director/Board Member Director/Board Member | |
DIREVO Industrial Biotechnology GmbH
 DIREVO Industrial Biotechnology GmbH Miscellaneous Commercial ServicesCommercial Services DIREVO Industrial Biotechnology GmbH provides bioengineering services for industrial, molecular biology, and reaction chemistry applications. It offers enzyme and strain engineering, application development, and process engineering services. The firm also offers research and development services for bio-fuel production. The company was founded in July 2008 and is headquartered in Cologne, Germany. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
Cell Medica Switzerland AG
 Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Investment Managers | President Private Equity Investor | |
APEIRON Biologics AG
 APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Cryotherapeutics SA
 Cryotherapeutics SA Medical SpecialtiesHealth Technology Cryotherapeutics SA develops and markets a cryotherapy system, with focus on highlighting the safety and efficacy of cryoneergy in the cardiovascular system. The firm specializes in the design of a proprietary system to be used in the treatment of coronary artery diseases that cause heart attacks. Its focus areas encompass technology research, system development, and early-stage product commercialization. The company was founded by Randell L. Werneth, John Yianni and Maurice Buchbinder on September 8, 2009 and is headquartered in Cologne, Germany. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
| UNIQURE N.V. | Biotechnology | Chief Executive Officer Founder | |
AyoxxA Living Health Technologies Pte Ltd.
 AyoxxA Living Health Technologies Pte Ltd. BiotechnologyHealth Technology AyoxxA Living Health Technologies Pte Ltd. engages in the research and development on biotechnology, life, and medical science. The company was founded by Andreas Schmidt in 2010 and is headquartered in Singapore. | Biotechnology | Chief Executive Officer Founder | |
| The Wharton School of the University of Pennsylvania | College/University | Undergraduate Degree Masters Business Admin | |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Biotechnology | Director/Board Member Director/Board Member | |
Inotrem SA
 Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
Rigontec GmbH
 Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Chairman Director/Board Member | |
Nouscom AG
 Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Founder Founder Founder | |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Mediar Therapeutics, Inc.
 Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| HOOKIPA PHARMA INC. | Biotechnology | Director/Board Member Chief Executive Officer Chairman Founder Director/Board Member Director/Board Member Founder Director/Board Member Founder Founder | |
STipe Therapeutics ApS
 STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
GeneSpire Srl
 GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy. | Biotechnology | Chairman Director/Board Member | |
Reithera Srl
 Reithera Srl Real Estate Investment TrustsFinance Reithera Srl is a biotech company based in Rome, Italy. The Italian company specializes in viral vector production and is a leading contract development and manufacturing organization. The company has a new 1,500 sq.m. facility that has been granted operational authorization from AIFA, the Italian Medicines Agency, which will allow them to consolidate their competitive position. Reithera's international team has contributed to several research projects aimed at unlocking the potential of innovative prophylactic and therapeutic programs. The company aims to unlock the potential of vector gene-delivery platforms by exploiting adenovirus, MVA, AAV, helper-dependent vectors, and rhabdovirus. The CEO of the company is Antonella Folgori. | Real Estate Investment Trusts | Founder Founder Chief Executive Officer | |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member |
Statistics
International
| Switzerland | 18 |
| Germany | 12 |
| United States | 6 |
| Italy | 4 |
| France | 4 |
Sectoral
| Health Technology | 30 |
| Consumer Services | 11 |
| Commercial Services | 7 |
| Finance | 5 |
| Technology Services | 2 |
Operational
| Director/Board Member | 447 |
| Corporate Officer/Principal | 118 |
| Chairman | 112 |
| Founder | 63 |
| Chief Executive Officer | 62 |
Most connected contacts
| Insiders | |
|---|---|
| Bradley Bolzon | 41 |
| Regina Hodits | 34 |
| Shelley Chu | 31 |
| Russell Greig | 31 |
| Gerald Heinz Möller | 29 |
| Florent Gros | 28 |
| Sten Verland | 28 |
| William Burns | 27 |
| Gerhard Ries | 27 |
| Graziano Seghezzi | 26 |
| Daniel Vasella | 25 |
| Joachim Rothe | 22 |
| Reinhard Ambros | 20 |
| Michael Kelly | 19 |
| Philippe Dro | 18 |
- Stock Market
- Insiders
- Markus Hosang
- Company connections
